Uncategorized - malecare.org

Clinical Benefit of Docetaxel or Enzalutamide After Progression on First-Line Abiraterone and Prednisone in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) *

Abiraterone acetate (AA) or Zytiga has demonstrated a survival benefit in the pre-chemotherapy setting for men with advanced prostate cancer that has become castrate resistant (mCRPC). As a result it is in widespread clinical use in the United States prior to the use of chemotherapy with docetaxel. Since its FDA approval post chemotherapy there has [...]

By Malecare|2017-10-19T10:48:05-04:00August 20th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Cross Resistance, Drugs & Treatments, enzalutamide, Uncategorized, Understanding APC, Xtandi|0 Comments

Incidence of advanced prostate cancer in men under the age of 50 in the United States: A population-based study 1973-2010

Clouded in the murkiness of the debate surrounding the use of the PSA test is an increasing escalation of younger men (under the age of 50 years) being diagnosed with advanced prostate cancer. We know that there has been escalating incidence rate (IR) of prostate cancer PC noted in the last two decades. Many have [...]

By Malecare|2017-10-19T10:48:05-04:00August 19th, 2014|Advanced Prostate Cancer, General Information, Uncategorized, Understanding APC|0 Comments

Efficacy of Combined Androgen Blockade with Zoledronic Acid *

It is known that Zoledronic acid (ZA) reduces the risk of developing skeletal-related events (SRE) which are caused by bone metastasis in prostate cancer (PCa). ZA also improves the quality of life (QOL). ZA has become a standard supportive therapy for men with prostate cancer who have bone metastasis. The big unknown is when should [...]

By Malecare|2017-10-19T10:48:05-04:00August 13th, 2014|ADT, Advanced Prostate Cancer, CAB, Combination Therapy, Drugs & Treatments, Uncategorized, Understanding APC|0 Comments

Study Shows That The Immune Responses Is Enhanced and Sustained When Provenge Is Given After Androgen Deprivation Therapy in Biochemically-Recurrent Prostate Cancer

Last April there was some preliminary data from the long-term Phase II STAND study presented at 29th Annual European Association of Urology (EAU) Congress that showed that sipuleucel-T (Provenge) when given after the start of androgen deprivation therapy (ADT) seemed to enhance and sustain the immune response in men with a biochemical failure (PSA only) [...]

By Malecare|2017-10-19T10:48:06-04:00August 12th, 2014|ADT, Advanced Prostate Cancer, Bio Chemical Recurrence, Drugs & Treatments, General Information, Provenge, survival, Uncategorized, Understanding APC|2 Comments

Bone Metastases and Prostate Cancer

The vast majority of men with advanced prostate cancer will eventually develop bone metastases. Given this fact it is important to understand what is meant by the term bone metastases. Bones serve as the supporting framework of our bodies. Like the rest of us bones are constructed of cells. These cells compose a network or [...]

By Malecare|2014-08-08T09:18:24-04:00August 8th, 2014|Advanced Prostate Cancer, Bone Health, Bone Metastases, Quality of Life, Uncategorized, Understanding APC|0 Comments